{"id":"W2130570549","doi":"10.1016/s0140-6736(13)60683-2","title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","year":2013,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":724,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Mitsubishi Tanabe Pharma Corporation","keywords":"Glimepiride; Medicine; Canagliflozin; Metformin; Type 2 diabetes; Population; Internal medicine; Randomized controlled trial; Diabetes mellitus; Clinical endpoint; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03620259462299996,"score_gpt":0.284852838621018,"score_spread":0.248650243998018,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}